Brought to you by 
Regeneron and bluebird bio enter cell therapy pact
Aug 2018
Executive Summary
Regeneron Pharmaceuticals Inc. and bluebird bio Inc. will lean on each other’s platform discoveries to together discover and develop antibodies and T-cell receptors directed against tumor-specific proteins and peptides.
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Co-Promotion
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Regeneron and bluebird bio enter cell therapy pact
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice